SERPINA1 and metabolic dysfunction-associated steatohepatitis: Identifying biomarkers that indicate lobular inflammation and hepatocyte ballooning as well as fibrosis such as AAT-A3F can lead to early diagnosis and treatment of NASH, which helps reduce mortality.